# ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

Source: https://onco.cc/trials/nct06998407/  
OnCo record `nct06998407` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AVZO-021 and Fulvestrant in advanced solid tumours, run by Avenzo Therapeutics, Inc., now recruiting.

## Summary

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06998407 by Avenzo Therapeutics, Inc., with 380 participants planned, started 2025-08-20 and due to reach its primary completion in 2028-08. Interventions recorded: AVZO-021, Fulvestrant, Letrozole and AVZO-023.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06998407
- Phase: 1/2
- Setting: A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-023 as a Single Agent, and in Combination With AVZO-021 and/or Endocrine Therapy in Patients With Advanced Solid Tumors
- Sponsor: Avenzo Therapeutics, Inc.
- Enrolled: 380

## Sources

- ClinicalTrials.gov NCT06998407: https://clinicaltrials.gov/study/NCT06998407

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [AVZO-021](https://onco.cc/drugs/avzo-021/), [AVZO-023](https://onco.cc/drugs/avzo-023/), [Fulvestrant](https://onco.cc/drugs/fulvestrant/)
- companies: [Avenzo Therapeutics](https://onco.cc/companies/avenzo/)

---
JSON: https://onco.cc/api/v1/entities/nct06998407.json